Diagnostics
The year kicked off with a bang as multiple companies raced to a public listing.
This liquid biopsy uses a panel of peptide biosensors to analyze protein activity from a blood sample and provide actionable readouts of the disease state.
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA’s signal to start shipping the vaccines.
C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located.
Depression is the first indication, but other neurological conditions are being planned.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
PRESS RELEASES